NEWS COMMENTARY

Scripps Institute launches DETECT, a research study for the rapid detection of viral outbreaks leveraging digital biomarkers

Published:
March 25, 2020
Coverage:
Digital Transformation More...
Activities:
Project
Very important

The study is not only timely but also groundbreaking in that it is device-agnostic and driving a pool of data notably not siloed by device manufacturers. The study will run for two years, which roughly aligns with projections for vaccine availability for COVID-19, and will be important not only for early front-line detection leading up to a vaccine being available to the public but also for population health management after the current crisis has passed. Clients should be looking to partner with companies running similar studies for digital biomarkers, such as Oura, to play a key role in this evolving global situation and, just as importantly, to keep a relevant place in the healthcare conversation after it is over.

For the original news article, click here .


Further Reading

Efficiency from digital tools in healthcare: The Molecular Medicine Tri Conference 2020 in three quotes from key healthcare opinion leaders

Analyst Insight | April 03, 2020

Lux Research recently attended the Molecular Medicine Tri Conference in San Francisco, California. The globally renowned conference hosted many attendees from academia, the medical professional community, and the medical industry, including major pharmaceuticals and medical device manufacturers. One... Not part of subscription

U.S. Air Force to provide free home testing kits for fertility through MFB contract

News Commentary | July 17, 2020

Fertility testing is often done in doctors' offices, but it is increasingly possible to move the provision of this kind of care into the home with mail‑in testing services. Home testing has been gaining popularity for years but is being accelerated by COVID‑19, where there is a need to outsource as ... To read more, click here.

Third resignation from FDA panel over approval of Biogen's Alzheimer's drug underscores challenges in clinical trial data interpretation

News Commentary | June 14, 2021

This is the third high‑profile resignation within a week of the controversial approval of Biogen's Alzheimer's disease (AD) medication by the U.S. FDA, which has been described as a "dangerous and confusing precedent." While the exact pathophysiology will continue to be an issue of debate among ... Not part of subscription